Morgan Stanley’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $237M | Buy |
436,699
+27,411
| +7% | +$15.4M | 0.01% | 917 |
|
|
2026
Q1 | $243M | Buy |
409,288
+20,013
| +5% | +$9.97M | 0.01% | 848 |
|
|
2025
Q4 | $190M | Sell |
389,275
-49,529
| -11% | -$23.1M | 0.01% | 973 |
|
|
2025
Q3 | $184M | Buy |
438,804
+41,290
| +10% | +$13.9M | 0.01% | 984 |
|
|
2025
Q2 | $114M | Sell |
397,514
-23,281
| -6% | -$6.96M | 0.01% | 1223 |
|
|
2025
Q1 | $130M | Buy |
420,795
+9,043
| +2% | +$3.1M | 0.01% | 1075 |
|
|
2024
Q4 | $145M | Buy |
411,752
+10,289
| +3% | +$3.78M | 0.01% | 1000 |
|
|
2024
Q3 | $144M | Sell |
401,463
-405,525
| -50% | -$137M | 0.01% | 1002 |
|
|
2024
Q2 | $257M | Buy |
806,988
+270,780
| +50% | +$71.7M | 0.02% | 685 |
|
|
2024
Q1 | $123M | Buy |
536,208
+76,476
| +17% | +$17.3M | 0.01% | 1055 |
|
|
2023
Q4 | $101M | Buy |
459,732
+105,331
| +30% | +$24.3M | 0.01% | 1141 |
|
|
2023
Q3 | $80M | Buy |
354,401
+45,625
| +15% | +$10.5M | 0.01% | 1207 |
|
|
2023
Q2 | $68.2M | Sell |
308,776
-34,116
| -10% | -$7.56M | 0.01% | 1326 |
|
|
2023
Q1 | $76.8M | Sell |
342,892
-45,913
| -12% | -$11.3M | 0.01% | 1217 |
|
|
2022
Q4 | $108M | Buy |
388,805
+132,795
| +52% | +$33.5M | 0.01% | 975 |
|
|
2022
Q3 | $53.6M | Sell |
256,010
-89,313
| -26% | -$20M | 0.01% | 1267 |
|
|
2022
Q2 | $81.4M | Sell |
345,323
-37,034
| -10% | -$7.53M | 0.01% | 1053 |
|
|
2022
Q1 | $68.6M | Buy |
382,357
+232,759
| +156% | +$44.3M | 0.01% | 1088 |
|
|
2021
Q4 | $32.3M | Buy |
149,598
+40,350
| +37% | +$7.92M | ﹤0.01% | 1685 |
|
|
2021
Q3 | $20.2M | Sell |
109,248
-20,742
| -16% | -$4.09M | ﹤0.01% | 2077 |
|
|
2021
Q2 | $23.3M | Buy |
129,990
+92,346
| +245% | +$17.6M | ﹤0.01% | 1989 |
|
|
2021
Q1 | $6.3M | Sell |
37,644
-8,391
| -18% | -$1.4M | ﹤0.01% | 3167 |
|
|
2020
Q4 | $6.99M | Buy |
46,035
+21,580
| +88% | +$2.83M | ﹤0.01% | 2899 |
|
|
2020
Q3 | $2.47M | Buy |
24,455
+7,525
| +44% | +$826K | ﹤0.01% | 3460 |
|
|
2020
Q2 | $2.05M | Sell |
16,930
-11,301
| -40% | -$1.27M | ﹤0.01% | 3570 |
|
|
2020
Q1 | $2.68M | Sell |
28,231
-125,654
| -82% | -$11.9M | ﹤0.01% | 3091 |
|
|
2019
Q4 | $13.6M | Buy |
153,885
+91,200
| +145% | +$8.02M | ﹤0.01% | 2068 |
|
|
2019
Q3 | $5M | Sell |
62,685
-88,767
| -59% | -$7.15M | ﹤0.01% | 2876 |
|
|
2019
Q2 | $11.8M | Sell |
151,452
-9,305
| -6% | -$870K | ﹤0.01% | 1978 |
|
|
2019
Q1 | $18.9M | Sell |
160,757
-27,789
| -15% | -$3.24M | 0.01% | 1481 |
|
|
2018
Q4 | $20.5M | Sell |
188,546
-55,082
| -23% | -$6.39M | 0.01% | 1430 |
|
|
2018
Q3 | $31.2M | Buy |
243,628
+21,129
| +9% | +$2.61M | 0.01% | 1289 |
|
|
2018
Q2 | $25.2M | Buy |
222,499
+67,060
| +43% | +$7.37M | 0.01% | 1432 |
|
|
2018
Q1 | $17.5M | Sell |
155,439
-18,411
| -11% | -$2.34M | ﹤0.01% | 1794 |
|
|
2017
Q4 | $25.7M | Sell |
173,850
-342,588
| -66% | -$43.6M | 0.01% | 1453 |
|
|
2017
Q3 | $60.5M | Sell |
516,438
-146,511
| -22% | -$18.7M | 0.02% | 797 |
|
|
2017
Q2 | $86M | Buy |
662,949
+12,753
| +2% | +$1.59M | 0.03% | 625 |
|
|
2017
Q1 | $88M | Buy |
650,196
+195,147
| +43% | +$29.6M | 0.03% | 628 |
|
|
2016
Q4 | $65.3M | Buy |
455,049
+92,633
| +26% | +$11.8M | 0.02% | 728 |
|
|
2016
Q3 | $42.8M | Sell |
362,416
-33,758
| -9% | -$4.06M | 0.01% | 933 |
|
|
2016
Q2 | $42M | Buy |
396,174
+56,510
| +17% | +$6.3M | 0.02% | 900 |
|
|
2016
Q1 | $37.8M | Buy |
339,664
+17,499
| +5% | +$2.21M | 0.01% | 916 |
|
|
2015
Q4 | $50.5M | Buy |
322,165
+24,130
| +8% | +$3.51M | 0.02% | 778 |
|
|
2015
Q3 | $39.1M | Buy |
298,035
+12,919
| +5% | +$2.07M | 0.01% | 934 |
|
|
2015
Q2 | $49.6M | Sell |
285,116
-25,947
| -8% | -$4.67M | 0.02% | 868 |
|
|
2015
Q1 | $53.6M | Sell |
311,063
-15,928
| -5% | -$2.43M | 0.02% | 814 |
|
|
2014
Q4 | $42.3M | Buy |
326,991
+89,203
| +38% | +$11.5M | 0.02% | 946 |
|
|
2014
Q3 | $30.6M | Sell |
237,788
-107,825
| -31% | -$11.1M | 0.01% | 1115 |
|
|
2014
Q2 | $30.6M | Buy |
345,613
+43,189
| +14% | +$4.15M | 0.01% | 1098 |
|
|
2014
Q1 | $28.4M | Buy |
302,424
+101,805
| +51% | +$10.4M | 0.01% | 1097 |
|
|
2013
Q4 | $22.7M | Buy |
200,619
+19,434
| +11% | +$1.75M | 0.01% | 1253 |
|
|
2013
Q3 | $14.3M | Buy |
181,185
+5,833
| +3% | +$426K | 0.01% | 1489 |
|
|
2013
Q2 | $11.5M | Buy |
+175,352
| New | +$11.3M | 0.01% | 1590 |
|
Other funds holding UTHR
ACA
JT
Morgan Stanley's UTHR Position: Q2 2026 in Review
Morgan Stanley increased its United Therapeutics (UTHR) stake by 6.7% in Q2 2026, buying an estimated $15.4M and bringing the position to 436,699 shares worth $237M. The position accounts for 0.01% of the portfolio, ranked #917.
Morgan Stanley first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $257M in Q2 2024. 876 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Morgan Stanley held 436,699 shares of United Therapeutics worth $237M as of Q2 2026.
- Morgan Stanley bought 27,411 United Therapeutics shares in Q2 2026, an estimated $15.4M.
- United Therapeutics made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #917 holding.
- Morgan Stanley first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Morgan Stanley's United Therapeutics position peaked at $257M in Q2 2024.
- 876 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.